Acrux (ASX:ACR) Institutional Ownership : 0.26% (As of Apr. 26, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Acrux Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Acrux's institutional ownership is 0.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Acrux's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Acrux's Float Percentage Of Total Shares Outstanding is 0.00%.

Acrux Institutional Ownership Historical Data

The historical data trend for Acrux's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Institutional Ownership Chart

Acrux Historical Data

The historical data trend for Acrux can be seen below:

	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-11-30	2021-12-31	2022-01-31	2022-02-28	2022-03-31	2022-12-31
Institutional Ownership	5.70	5.70	5.70	5.69	5.69	5.69	5.69	5.69	5.68	0.26

Acrux Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Acrux (ASX:ACR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ARUXF:USA FJY:Germany

Address

103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003

Website

https://www.acrux.com.au

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.